Claritev (NYSE:CTEV) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Claritev (NYSE:CTEV) has earned an average rating of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $33.6667.

Several analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Claritev in a research note on Friday, March 27th. Wall Street Zen downgraded Claritev from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Piper Sandler set a $61.00 price objective on Claritev in a research note on Wednesday, June 3rd. UBS Group reaffirmed a “buy” rating on shares of Claritev in a research note on Tuesday, February 24th. Finally, Barclays assumed coverage on Claritev in a research note on Friday, April 24th. They set an “overweight” rating and a $28.00 price objective for the company.

Claritev Stock Down 4.5%

CTEV opened at $30.58 on Friday. The business has a 50 day moving average price of $22.94 and a two-hundred day moving average price of $26.66. The company has a market cap of $521.39 million, a PE ratio of -1.76 and a beta of 0.77. Claritev has a 52 week low of $11.50 and a 52 week high of $74.07.

Hedge Funds Weigh In On Claritev

Large investors have recently modified their holdings of the business. State of Wyoming purchased a new position in shares of Claritev during the 4th quarter worth approximately $25,000. Public Employees Retirement System of Ohio purchased a new position in shares of Claritev during the 1st quarter worth approximately $38,000. Ameritas Investment Partners Inc. purchased a new position in shares of Claritev during the 3rd quarter worth approximately $42,000. Legal & General Group Plc purchased a new position in shares of Claritev during the 3rd quarter worth approximately $45,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Claritev during the 4th quarter worth approximately $45,000. 87.15% of the stock is owned by hedge funds and other institutional investors.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.